Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| mast cell | 31 studies | 59% ± 18% | |
| ciliated cell | 6 studies | 19% ± 4% | |
| pancreatic A cell | 3 studies | 42% ± 16% | |
| epithelial cell | 3 studies | 23% ± 5% | |
| fibroblast | 3 studies | 18% ± 2% | |
| GABAergic neuron | 3 studies | 31% ± 7% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| pancreas | 3 studies | 33% ± 15% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| pancreas | 99% | 1848.88 | 326 / 328 | 96% | 29.05 | 171 / 178 |
| lung | 100% | 2815.67 | 577 / 578 | 94% | 19.16 | 1091 / 1155 |
| thymus | 100% | 1731.38 | 652 / 653 | 94% | 18.98 | 570 / 605 |
| stomach | 100% | 2015.07 | 359 / 359 | 93% | 16.76 | 266 / 286 |
| intestine | 100% | 3197.52 | 965 / 966 | 93% | 18.78 | 489 / 527 |
| kidney | 100% | 2012.17 | 89 / 89 | 93% | 16.82 | 834 / 901 |
| breast | 100% | 2794.65 | 458 / 459 | 92% | 20.99 | 1034 / 1118 |
| adrenal gland | 100% | 3376.29 | 258 / 258 | 92% | 20.31 | 212 / 230 |
| ovary | 99% | 1405.60 | 179 / 180 | 88% | 12.83 | 378 / 430 |
| esophagus | 100% | 2001.63 | 1439 / 1445 | 83% | 11.22 | 152 / 183 |
| bladder | 100% | 2699.05 | 21 / 21 | 81% | 14.98 | 409 / 504 |
| brain | 81% | 1430.10 | 2150 / 2642 | 100% | 24.56 | 702 / 705 |
| prostate | 100% | 2673.76 | 245 / 245 | 77% | 8.50 | 388 / 502 |
| uterus | 99% | 1548.87 | 169 / 170 | 74% | 11.53 | 341 / 459 |
| skin | 99% | 2845.57 | 1784 / 1809 | 57% | 5.89 | 270 / 472 |
| adipose | 100% | 2158.18 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| spleen | 100% | 1140.45 | 241 / 241 | 0% | 0 | 0 / 0 |
| blood vessel | 100% | 2482.58 | 1331 / 1335 | 0% | 0 | 0 / 0 |
| liver | 46% | 283.12 | 104 / 226 | 36% | 3.45 | 147 / 406 |
| tonsil | 0% | 0 | 0 / 0 | 82% | 7.80 | 37 / 45 |
| lymph node | 0% | 0 | 0 / 0 | 79% | 7.26 | 23 / 29 |
| eye | 0% | 0 | 0 / 0 | 57% | 7.46 | 46 / 80 |
| heart | 54% | 419.51 | 468 / 861 | 0% | 0 | 0 / 0 |
| peripheral blood | 34% | 277.92 | 314 / 929 | 0% | 0 | 0 / 0 |
| muscle | 31% | 201.22 | 245 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0005654 | Cellular component | nucleoplasm |
| GO_0005515 | Molecular function | protein binding |
| Gene name | VWA5A |
| Protein name | cDNA FLJ55206, highly similar to Loss of heterozygosity 11 chromosomal region 2 gene A protein (von Willebrand factor A domain containing 5A) von Willebrand factor A domain-containing protein 5A (Breast cancer suppressor candidate 1) (BCSC-1) (Loss of heterozygosity 11 chromosomal region 2 gene A protein) |
| Synonyms | BCSC1 LOH11CR2A |
| Description | FUNCTION: May play a role in tumorigenesis as a tumor suppressor. Altered expression of this protein and disruption of the molecular pathway it is involved in, may contribute directly to or modify tumorigenesis. |
| Accessions | ENST00000456829.7 [O00534-1] ENST00000361352.9 [O00534-3] ENST00000392748.5 [O00534-1] ENST00000392744.4 ENST00000449321.5 [O00534-3] O00534 B4DHS6 |
